Diana Ernst, RPh

Most Recent Articles by Diana Ernst, RPh

Psychiatric Adverse Effects of Disease-Modifying Therapies Assessed in MS Patients

By Sep 25, 2018

The primary outcome measure of the study was the frequency of any adverse psychiatric effect observed during treatment with one of these agents.

Copiktra Approved for Relapsed/Refractory CLL/SLL, Follicular Lymphoma

By Sep 25, 2018

In a clinical trial involving patients with CLL (N=312) or SLL (N=7), median progression-free survival (PFS) was 16.4 months for patients treated with duvelisib vs 9.1 months for those treated with ofatumumab.

Positive Results for Soliris in Neuromyelitis Optica Spectrum Disorder Trial

By Sep 24, 2018

In the PREVENT study, the safety and efficacy of Soliris was compared to placebo in patients with AQP4 auto antibody-positive NMOSD (N=143).

Patient Develops Rare Extrapulmonary Manifestation of Tuberculosis

By Sep 21, 2018

The patient, a 42-year-old female with systemic lupus erythematosus treated with mycophenolate mofetil and prednisone, reported swelling and pain in the fifth finger of her left hand for about 1-week.

Xelpros Approved for Open-Angle Glaucoma, Ocular Hypertension

By Sep 14, 2018

Xelpros contains latanoprost, a prostaglandin F2α analogue that is believed to reduce IOP by increasing the outflow of aqueous humor.

More Articles by Diana Ernst, RPh